HomeCompareLYPHF vs DIVO

LYPHF vs DIVO: Dividend Comparison 2026

LYPHF yields 529.73% · DIVO yields 6.62%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LYPHF wins by $320.3K in total portfolio value
10 years
LYPHF
LYPHF
● Live price
529.73%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$351.3K
Annual income
$921.47
Full LYPHF calculator →
DIVO
DIVO
● Live price
6.62%
Share price
$44.00
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.0K
Annual income
$1,008.47
Full DIVO calculator →

Portfolio growth — LYPHF vs DIVO

📍 LYPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLYPHFDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LYPHF + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LYPHF pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LYPHF
Annual income on $10K today (after 15% tax)
$45,027.15/yr
After 10yr DRIP, annual income (after tax)
$783.25/yr
DIVO
Annual income on $10K today (after 15% tax)
$562.67/yr
After 10yr DRIP, annual income (after tax)
$857.20/yr
At 15% tax rate, DIVO beats the other by $73.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LYPHF + DIVO for your $10,000?

LYPHF: 50%DIVO: 50%
100% DIVO50/50100% LYPHF
Portfolio after 10yr
$191.1K
Annual income
$964.98/yr
Blended yield
0.50%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LYPHF buys
0
DIVO buys
0
No recent congressional trades found for LYPHF or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLYPHFDIVO
Forward yield529.73%6.62%
Annual dividend / share$2.00$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0%
Portfolio after 10y$351.3K$31.0K
Annual income after 10y$921.47$1,008.47
Total dividends collected$211.1K$8.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: LYPHF vs DIVO ($10,000, DRIP)

YearLYPHF PortfolioLYPHF Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$37,187$26,486.56$11,362$661.96+$25.8KLYPHF
2$85,815$46,025.42$12,860$702.91+$73.0KLYPHF
3$141,454$49,631.95$14,504$743.56+$127.0KLYPHF
4$189,585$38,229.58$16,303$783.73+$173.3KLYPHF
5$226,799$23,942.82$18,268$823.31+$208.5KLYPHF
6$256,060$13,384.38$20,408$862.17+$235.7KLYPHF
7$281,045$7,061.29$22,737$900.20+$258.3KLYPHF
8$304,340$3,621.64$25,266$937.31+$279.1KLYPHF
9$327,476$1,832.63$28,008$973.42+$299.5KLYPHF
10$351,321$921.47$30,977$1,008.47+$320.3KLYPHF

LYPHF vs DIVO: Complete Analysis 2026

LYPHFStock

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

Full LYPHF Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this LYPHF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LYPHF vs SCHDLYPHF vs JEPILYPHF vs OLYPHF vs KOLYPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.